Fulgent Genetics insider discloses 696-share sale; retained ownership remains substantial
Rhea-AI Filing Summary
Xie Jian, President and COO of Fulgent Genetics (FLGT) reported a sale of 696 shares on 08/25/2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/23/2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, with a reported weighted-average price of $21.5016. After the sale, the reporting person beneficially owns 366,448 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust, of which he serves on the investment committee and for which he disclaims beneficial interest except for any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Positive
- Sale documented as tax-withholding on RSU vesting, indicating administrative rather than opportunistic trading
- Substantial remaining ownership: 366,448 shares directly and 220,816 indirectly via trust
- Complete disclosure of sale price range ($21.46–$21.57) and weighted-average price ($21.5016)
Negative
- Reduction of direct holdings by 696 shares recorded on 08/25/2025
Insights
TL;DR: Routine insider sale of 696 shares to cover RSU tax withholding; ownership remains substantial.
The reported disposition is explicitly a sale to satisfy tax withholding on RSU vesting, not an open-market reduction of long-term holdings. The weighted-average sale price of $21.5016 and the small share count (696) indicate the transaction is administrative in nature. Post-transaction direct ownership of 366,448 shares plus 220,816 indirectly held suggests continued material insider alignment with shareholders. No derivative transactions or other dispositions are reported.
TL;DR: Disclosure is standard and complete: sale is identified, source of sale explained, and trust holdings disclosed.
The filing clearly states the purpose of the sale (tax withholding) and discloses indirect holdings via The Hsieh Family Dynasty Trust, including the reporting person’s role on the trust investment committee and disclaimer of beneficial interest beyond pecuniary exposure. Signature by an attorney-in-fact is documented. This meets Section 16 transparency requirements and does not indicate any governance or compliance irregularity based on the provided facts.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 696 | $21.5016 | $15K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
